Krishna Institute of Medical Sciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+28.6%+21.5%+13.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+2.4%+22.2%+6.0%
−14.3%+22.6%+4.0%
−41.7%+23.4%−8.1%
−37.3%−75.2%−7.8%
+35.3%+48.9%+31.0%
+5.8%+15.6%+8.0%
−12.2%+11.7%+20.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

KIMS₹665.00

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹26,600 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+13.7+21.5+28.6—
EBITDA Growth—+6.0+22.2+2.4—
EBIT Growth—+4.0+22.6-14.3—
Net Income Growth—-8.1+23.4-41.7—
EPS Growth—-7.8-75.2-37.3—
Total Assets Growth—+31.0+48.9+35.3—
Total Equity Growth—+8.0+15.6+5.8—
Cash from Operations Growth—+20.6+11.7-12.2—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.